Kineta to Present at September 2020 Virtual Investor Conferences

Seattle, WA — (September 11, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta will be presenting at multiple virtual investor events in September 2020. Shawn Iadonato, Kineta Chief Executive Officer and Craig Philips, President, will present an overview of the company with a focus on its novel VISTA immuno-oncology program at the following events:

Opal Direct Investment Forum 2020
September 10, 2020 at 10:10-10:30AM Pacific Time

H.C. Wainwright 22nd Annual Global Investment Conference
September 15, 2020 at 6:30-6:50AM Pacific time

OTC Markets Group Life Sciences Investor Forum
September 17, 2020 at 1:00-1:30 Pacific time

FORCE Wealth Virtual Investor Conference
September 30, 2020 at 10:00-11:00AM Pacific Time


Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in immunology to advance a focused pipeline of investigational drugs in oncology, neuroscience and biodefense. We actively collaborate with a broad array of private, government and industry partners to advance our innovative products. For more information on Kineta visit our website,, follow us on Twitter at @kinetabio, LinkedIn and Like us on

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s and Kineta Chronic Pain, LLC’s (KCP) plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s and KCP’s businesses which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and neither Kineta nor KCP undertake any obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Jacques Bouchy
(206) 378-0400